George J. Yohrling - Publications

Johnson and Johnson, Manor, TX, United States 
Neurodegenerative disease

14/18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Huang Y, Strobel ED, Ho CY, Reynolds CH, Conway KA, Piesvaux JA, Brenneman DE, Yohrling GJ, Moore Arnold H, Rosenthal D, Alexander RS, Tounge BA, Mercken M, Vandermeeren M, Parker MH, et al. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Bioorganic & Medicinal Chemistry Letters. 20: 3158-60. PMID 20399652 DOI: 10.1016/j.bmcl.2010.03.097  0.48
2009 Liu Y, Yohrling GJ, Wang Y, Hutchinson TL, Brenneman DE, Flores CM, Zhao B. Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Research. 83: 66-72. PMID 19013768 DOI: 10.1016/j.eplepsyres.2008.09.006  0.48
2008 Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, Clark TW, Bouzou B, Cha JH. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 10720-33. PMID 18923047 DOI: 10.1523/JNEUROSCI.2126-08.2008  0.48
2007 Yohrling GJ, Felsenstein KM, Conway KA, Zupa-Fernandez A, Brenneman DE, Arnold HM. A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta. Current Alzheimer Research. 4: 297-303. PMID 17627487 DOI: 10.2174/156720507781077269  0.48
2007 Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Human Molecular Genetics. 16: 1293-306. PMID 17409194 DOI: 10.1093/hmg/ddm078  0.48
2006 Sadri-Vakili G, Menon AS, Farrell LA, Keller-McGandy CE, Cantuti-Castelvetri I, Standaert DG, Augood SJ, Yohrling GJ, Cha JH. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. The European Journal of Neuroscience. 23: 3171-5. PMID 16820007 DOI: 10.1111/j.1460-9568.2006.04871.x  0.48
2006 Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiology of Disease. 22: 233-41. PMID 16442295 DOI: 10.1016/j.nbd.2005.11.001  0.48
2004 Braveman MW, Chen-Plotkin AS, Yohrling GJ, Cha JH. Chromatin immunoprecipitation technique for study of transcriptional dysregulation in intact mouse brain. Methods in Molecular Biology (Clifton, N.J.). 277: 261-76. PMID 15201461 DOI: 10.1385/1-59259-804-8:261  0.48
2003 Yohrling GJ, Jiang GC, DeJohn MM, Miller DW, Young AB, Vrana KE, Cha JH. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Research. Molecular Brain Research. 119: 28-36. PMID 14597227 DOI: 10.1016/j.molbrainres.2003.08.009  0.48
2003 Yohrling GJ, Farrell LA, Hollenberg AN, Cha JH. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Molecular and Cellular Neurosciences. 23: 28-38. PMID 12799135 DOI: 10.1016/S1044-7431(03)00032-0  0.48
2000 Freeman WM, Yohrling GJ, Daunais JB, Gioia L, Hart SL, Porrino LJ, Davies HM, Vrana KE. A cocaine analog, 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT), reduces tyrosine hydroxylase in the mesolimbic dopamine pathway. Drug and Alcohol Dependence. 61: 15-21. PMID 11064180 DOI: 10.1016/S0376-8716(00)00119-8  0.32
2000 Yohrling GJ, Jiang GC, Mockus SM, Vrana KE. Intersubunit binding domains within tyrosine hydroxylase and tryptophan hydroxylase. Journal of Neuroscience Research. 61: 313-20. PMID 10900078 DOI: 10.1002/1097-4547(20000801)61:3<313::AID-JNR9>3.0.CO;2-9  0.32
1999 Yohrling GJ, Mockus SM, Vrana KE. Identification of amino-terminal sequences contributing to tryptophan hydroxylase tetramer formation. Journal of Molecular Neuroscience : Mn. 12: 23-34. PMID 10636468 DOI: 10.1385/JMN:12:1:23  0.32
1998 Mockus SM, Yohrling GJ, Vrana KE. Tyrosine hydroxylase and tryptophan hydroxylase do not form heterotetramers. Journal of Molecular Neuroscience : Mn. 10: 45-51. PMID 9589369 DOI: 10.1007/BF02737084  0.32
Low-probability matches
2000 Jiang GC, Yohrling GJ, Schmitt JD, Vrana KE, Yohrling GJ, Schmitt IV. Identification of substrate orienting and phosphorylation sites within tryptophan hydroxylase using homology-based molecular modeling. Journal of Molecular Biology. 302: 1005-17. PMID 10993738 DOI: 10.1006/jmbi.2000.4097  0.01
2019 Anderson KE, Griffin J, Kinel A, Shaikh AR, Olofintuyi T, Ramirez S, Steinman J, Yohrling GJ, Kinel S. Quality of Care for Huntington's Disease in the United States: Findings from a National Survey of Patients and Caregivers. Journal of Huntington's Disease. PMID 31594241 DOI: 10.3233/JHD-190380  0.01
2017 Yohrling GJ, Vetter LA. Stewarding Hope: The Evolving Landscape of Huntington's Disease Science Communications. Journal of Huntington's Disease. PMID 28128771 DOI: 10.3233/JHD-160230  0.01
2016 Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. Journal of Huntington's Disease. 5: 395-403. PMID 27983566 DOI: 10.3233/JHD-160228  0.01
Hide low-probability matches.